Search

Your search keyword '"Humira (Medication) -- Prices and rates"' showing total 17 results
Start Over Descriptor "Humira (Medication) -- Prices and rates"
17 results on '"Humira (Medication) -- Prices and rates"'

1. The Opaque Industry Secretly Inflating Prices for Prescription Drugs

Author

Robbins, Rebecca and Abelson, Reed

Subjects
CVS Health Corp. -- Prices and rates, CIGNA Corp. -- Prices and rates, Express Scripts Inc. -- Prices and rates, UnitedHealth Group Inc. -- Prices and rates, Health maintenance organizations -- Prices and rates, Employers, Drugs -- Prescribing, Drugstores -- Prices and rates, Americans, Company pricing policy, General interest, Humira (Medication) -- Prices and rates
Abstract

Byline: Rebecca Robbins and Reed Abelson Americans are paying too much for prescription drugs. It is a common, longstanding complaint. And the culprits seem obvious: Drug companies. Insurers. A dysfunctional [...]

Published
2024

2. The Opaque Industry Secretly Inflating Prices for Prescription Drugs

Author

Robbins, Rebecca and Abelson, Reed

Subjects
CVS Health Corp. -- Officials and employees, CIGNA Corp. -- Officials and employees, Express Scripts Inc. -- Officials and employees, UnitedHealth Group Inc. -- Officials and employees, Health maintenance organizations -- Prices and rates -- Officials and employees, Employers, Drugs -- Prescribing, Drugstores -- Officials and employees -- Prices and rates, Americans, Company pricing policy, News, opinion and commentary, Humira (Medication) -- Prices and rates
Abstract

Americans are paying too much for prescription drugs. It is a common, longstanding complaint. And the culprits seem obvious: Drug companies. Insurers. A dysfunctional federal government. But there is another [...]

Published
2024

3. AbbVie will feel the squeeze under new drug pricing law; Its blockbuster Humira is on a new list of 27 drugs that saw prices rise faster than inflation in 2022 -- triggering penalties and rebates under rules passed last year

Subjects
United States. Department of Health and Human Services -- Laws, regulations and rules, Social service -- Prices and rates, Pricing -- Laws, regulations and rules, Antiarthritic agents -- Prices and rates, Inflation (Finance) -- Laws, regulations and rules, Pharmaceutical industry -- Prices and rates -- Laws, regulations and rules, Government regulation, Product price, Company pricing policy, Business, Business, regional, Humira (Medication) -- Prices and rates
Abstract

Byline: Katherine Davis Humira, the rheumatoid arthritis medication made by pharmaceutical giant AbbVie, is among the first group of drugs that will face a penalty under a new law prohibiting [...]

Published
2023

4. Consumers, small businesses, taxpayers need relief from Big Pharma

Subjects
Pricing, Small business -- Arizona, Restraint of trade, Drugs -- Prescribing -- Prices and rates, Unfair competition (Commerce), Monopolies, Pharmaceutical industry -- Prices and rates, Small business, Product price, Company pricing policy, SOHO, News, opinion and commentary, Humira (Medication) -- Prices and rates
Abstract

Byline: Guest Opinion The pharmaceutical industry is putting a tremendous burden on Arizona taxpayers and small businesses by utilizing anti-competitive practices to undermine market forces in health care and engaging [...]

Published
2021

5. Adalimumab Biosimilars Insight by DelveInsight

Subjects
Psoriasis -- Forecasts and trends -- Reports, Rheumatoid factor -- Reports -- Forecasts and trends, Arthritis -- Reports -- Forecasts and trends, Adalimumab -- Prices and rates, Tumor necrosis factor -- Forecasts and trends -- Reports, Market trend/market analysis, Company pricing policy, Business, Business, international, Humira (Medication) -- Prices and rates
Abstract

M2 PRESSWIRE-November 30, 2021-: Adalimumab Biosimilars Insight by DelveInsight (C)1994-2021 M2 COMMUNICATIONS RDATE:30112021 DelveInsight's, 'Adalimumab Biosimilar Insight' report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs [...]

Published
2021

6. Drug prices are rising again

Author

Cunningham, Paige Winfield

Subjects
Pfizer Inc., Pharmaceutical industry, Antiarthritic agents -- Prices and rates, Inflation (Economics), Legislators, Drugs, Arthritis, Company pricing policy, General interest, News, opinion and commentary, Humira (Medication) -- Prices and rates
Abstract

Byline: Paige Winfield Cunningham Pharmaceutical makers are barely tapping the brakes when it comes to raising the price of their medications in 2020 - even after heavy pressure from lawmakers [...]

Published
2020

7. WYDEN LAUNCHES INVESTIGATION INTO ABBVIE TAX PRACTICES

Subjects
AbbVie Inc. -- Prices and rates -- Investigations, Tax rates -- Investigations, Drugs -- Prescribing, Pharmaceutical industry -- Investigations -- Prices and rates, Company legal issue, Company pricing policy, News, opinion and commentary, Imbruvica (Medication) -- Prices and rates, Humira (Medication) -- Prices and rates
Abstract

WASHINGTON, D.C. -- The following information was released by the U.S. Senate Committee on Finance, Majority Office: AbbVie average effective tax rate fell to 9.5 percent in 2018-2020, down from [...]

Published
2021

8. HEARING EXPOSES GREED OF DRUG CORPORATION ABBVIE

Subjects
Drugs -- Prices and rates, Company pricing policy, News, opinion and commentary, Imbruvica (Medication) -- Prices and rates, Humira (Medication) -- Prices and rates
Abstract

WASHINGTON, DC -- The following information was released by the Alliance for Retired Americans: According to a study released on May 18 by the U.S. House Oversight and Reform Committee, [...]

Published
2021

9. COMMITTEE TO HOLD HEARING WITH ABBVIE CEO AND EXPERTS ON PRICING PRACTICES FOR HUMIRA AND IMBRUVICA MAY

Subjects
AbbVie Inc. -- Political activity -- Prices and rates, Chief executive officers -- Political aspects -- Political activity, Drugs -- Prices and rates, Chairpersons -- Political activity -- Political aspects, Pharmaceutical industry -- Prices and rates -- Political aspects -- Political activity, Company pricing policy, News, opinion and commentary, Imbruvica (Medication) -- Prices and rates, Humira (Medication) -- Prices and rates
Abstract

WASHINGTON, DC -- The following information was released by the U.S. House of Representatives Committee on Oversight and Government Reform: On Tuesday, May 18, 2021, at 10:00 a.m., Rep. Carolyn [...]

Published
2021

10. Adalimumab Biosimilars Insight, 2020 | DelveInsight Report Analysis

Subjects
Pfizer Inc. -- Forecasts and trends, Psoriasis -- Forecasts and trends -- Reports, Rheumatoid factor -- Reports -- Forecasts and trends, Homeopathy -- Materia medica and therapeutics, Therapeutics -- Prices and rates, Arthritis -- Reports -- Forecasts and trends, Adalimumab -- Prices and rates, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Company pricing policy, Business, Business, international, Humira (Medication) -- Prices and rates
Abstract

M2 PRESSWIRE-March 5, 2021-: Adalimumab Biosimilars Insight, 2020 | DelveInsight Report Analysis (C)1994-2021 M2 COMMUNICATIONS RDATE:04032021 DelveInsight's, 'Adalimumab Biosimilar Insight, 2020,' report provides comprehensive insights about 35+ companies and 45+ [...]

Published
2021

11. AS DRUG PRICES KEEP RISING, STATE LAWMAKERS PROPOSE TOUGH NEW BILLS TO CURB THEM

Subjects
Drugs -- Prescribing, Pharmaceutical policy -- Political aspects, Company pricing policy, News, opinion and commentary, Humira (Medication) -- Prices and rates
Abstract

WASHINGTON, DC -- The following information was released by the Alliance for Retired Americans: By Harris Meyer Fed up with a lack of federal action to lower prescription drug costs, [...]

Published
2021

12. Autoimmune

Author

Knutsen, Rebecca Mayer

Subjects
Pfizer Inc., Eli Lilly and Co., Psoriasis, Pharmaceutical industry, Company pricing policy, Business, Health care industry, Cosentyx (Medication) -- Prices and rates, Humira (Medication) -- Prices and rates
Abstract

Biosimilars are threatening to chip away at established blockbusters. Industry giants are battling to devise better therapies for celiac, Crohn's and lupus even as they work around the clock to [...]

Published
2015

13. AbbVie's Humira defense may keep prices high, but it's still legal, judge rules

Author

Sagonowsky, Eric

Subjects
Defense industry -- Prices and rates, Drugs -- Prices and rates, Antitrust law, Defense industry, Antitrust issue, Company pricing policy, Pharmaceuticals and cosmetics industries, Humira (Medication) -- Prices and rates
Abstract

Byline: Eric Sagonowsky AbbVie reaps billions of dollars annually from its big-selling immunology medicine Humira, and, under deals with biosimilar makers, the drug is likely free from U.S. competition until [...]

Published
2020

14. The Health 202: Washington got stuck on lowering drug prices. Now they're rising again

Subjects
United States. Senate, Pfizer Inc., Pharmaceutical industry, Antiarthritic agents -- Prices and rates, Inflation (Economics), Legislators, Drugs, Arthritis, Company pricing policy, Business, Computers and office automation industries, Telecommunications industry, Humira (Medication) -- Prices and rates
Abstract

Byline: Paige Winfield Cunningham THE PROGNOSIS Pharmaceutical makers are barely tapping the brakes when it comes to raising the price of their medications in 2020 -- even after heavy pressure [...]

Published
2020

15. The Humira Play: Raise High Prices, Steadily

Author

Hakim, Danny

Subjects
Anti-inflammatory agents -- Prices and rates, Pharmaceutical industry -- Forecasts and trends, Biological products -- Forecasts and trends, Market trend/market analysis, Company pricing policy, General interest, News, opinion and commentary, Humira (Medication) -- Prices and rates
Abstract

Humira is the best-selling prescription drug in the world. You may have seen the commercials. Because of Humira, a woman with rheumatoid arthritis can wash her puppy in the bathtub, [...]

Published
2018

16. New drugs offer hope at huge price

Author

Merx, Katie

Subjects
Biological products industry -- Product development, Pharmaceutical industry -- Product development, Drugs -- Prescribing, Drugs -- Prices and rates, Company pricing policy, Business, Business, regional, General interest, Humira (Medication) -- Prices and rates
Published
2005

17. ABBOTT Laboratories. (Active Pharmaceutical Ingredient Watch)

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Prices and rates, Pharmaceutical industry -- Prices and rates, Antiarthritic agents -- Prices and rates, Company pricing policy, Business, Chemicals, plastics and rubber industries, Humira (Medication) -- Prices and rates
Abstract

ABBOTT Laboratories raised its 2003 sales guidance for rheumatoid arthritis drug Humira (adalimumab) by $50 million to $250 million. Guidance for 2004 remains unchanged at over $500 [...]

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results